Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

Introduction Incretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion. The first-in-class oral glucagon-like peptide-1 receptor agonist semaglutide has potent effects on glycaemic and weight control, but littl...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyu Yong Cho, Hiroki Yokoyama, Tatsuya Atsumi, Hiroshi Nomoto, Jun Takeuchi, So Nagai, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Hideaki Miyoshi, Shinji Taneda, Ichiro Sakuma, Sho Furusawa, Aika Miya, Hiraku Kameda
Format: Article
Language:English
Published: BMJ Publishing Group 2022-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/5/e056885.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/12/5/e056885.full

Similar Items